Stocks Touched New Highs: Ardelyx Inc (NASDAQ:ARDX), Durata Therapeutics Inc (NASDAQ:DRTX), Portola Pharmaceuticals Inc (NASDAQ:PTLA), Omeros Corporation (NASDAQ:OMER), Illumina (NASDAQ:ILMN)

Ardelyx (NASDAQ:ARDX) major shareholder Ventures Vii Lp Cmea acquired 316,826 shares of Ardelyx stock in a transaction dated Tuesday, June 24th. The shares were purchased at an average price of $14.00 per share, with a total value of $4,435,564.00. The transaction was disclosed in a filing with the Securities & Exchange Commission. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC. Ardelyx Inc (NASDAQ:ARDX) net profit margin is -33.00% and weekly performance is 25.83%. On last trading day company shares ended up $19.44. Ardelyx Inc (NASDAQ:ARDX) distance from 50-day simple moving average is 24.77%.

Durata Therapeutics (NASDAQ:DRTX) had its price objective raised by Roth Capital from $24.00 to $28.00 in a research report released on Tuesday morning. Durata Therapeutics Inc (NASDAQ:DRTX) shares advanced 2.05% in last trading session and ended the day on $17.88. DRTX its return on assets is -65.00%. Durata Therapeutics Inc (NASDAQ:DRTX) quarterly performance is 27.35%.

Portola Pharmaceuticals (NASDAQ:PTLA) CEO William Lis sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $29.23, for a total value of $292,300.00. The sale was disclosed in a document filed with the SEC. Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares moved up 2.56% in last trading session and was closed at $30.89, while trading in range of $30.11-$31.18. Portola Pharmaceuticals Inc (NASDAQ:PTLA) year to date performance is 19.96%.

Omeros (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764. Omeros Corporation (NASDAQ:OMER) ended the last trading day at $18.34. Company weekly volatility is calculated as 6.19% and price to cash ratio as 11.91. Omeros Corporation (NASDAQ:OMER) showed a positive weekly performance of 4.98%.

Illumina, Inc. (NASDAQ:ILMN) announced that it has entered into separate agreements with Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, under which they will use the HiSeq 2500 and consumables from Illumina to develop and perform non-invasive prenatal testing (NIPT). Biomnis plans to make NIPT available in France, Genoma plans to perform NIPT services in Italy, and the Center for Human Genetics and Laboratory Diagnostics will offer NIPT in Germany. Illumina, Inc. (NASDAQ:ILMN) net profit margin is 13.80% and weekly performance is 5.62%. On last trading day company shares ended up $180.46. Analysts mean target price for the company is $176.97. Illumina, Inc. (NASDAQ:ILMN) distance from 50-day simple moving average is 14.64%.